Canada: Canadian Court Nixes Class Action For Patent Abuse

The British Columbia Court of Appeal (BCCA), in Low v. Pfizer Canada Inc., has held that Canada's Patent Act provides a complete code that forecloses civil actions by consumers centred on breaches of the statute.


The decision relates to an application to certify a proposed class action, commenced by a representative plaintiff, Britton Low, against various Pfizer companies, alleging that Pfizer unlawfully abused the patent system with the result that purchasers of the drug VIAGRA were overcharged. The proposed class consists of B.C. purchasers of VIAGRA during the period of January 1, 2006 to November 30, 2012.

Mr. Low relied on the fact that Pfizer's patent for VIAGRA had been held to be invalid for insufficiency by the Supreme Court of Canada and the Federal Court. He therefore alleged that Pfizer's actions in enforcing its patent so as to prevent generic versions of VIAGRA from being marketed prior to the declaration of invalidity of the Pfizer patent constituted actionable torts.

More particularly, Mr. Low pleaded that Pfizer's actions constituted unlawful interference with economic relations and unjust enrichment.

Mr. Low sought certification of the class action in the British Columbia Supreme Court and was initially successful. The chambers judge held that it was not plain and obvious that the Patent Act barred the plaintiff's action. The judge held that a third proposed cause of action, waiver of tort, had no chance of success and so did not allow that part of the claim to proceed.


Pfizer appealed the lower court's certification of the class action to the British Columbia Court of Appeal. Pfizer argued that the Patent Act and certain regulations enacted pursuant to the Act provide a complete code that excludes common law remedies for a breach of the legislation. Pfizer further argued that Mr. Low's claim did not disclose a cause of action in either unlawful interference with economic relations or unjust enrichment.


The Patent Act establishes, among other things: (1) the circumstances under which a patent may be granted for an invention, (2) the grounds for invalidating a patent and (3) the remedies for patent infringement. The Act also contains provisions allowing the Commissioner of Patents to exercise certain powers (such as patent revocation or the granting of a compulsory licence) in enumerated circumstances of patent abuse.

The Patented Medicines (Notice of Compliance) Regulations (NOC Regulations), enacted pursuant to the Act, together with the Food and Drugs Act and associated regulations, govern the circumstances under which a generic manufacturer can obtain approval to market a generic version of a patented drug. The NOC Regulations provide a cause of action to a generic manufacturer in certain circumstances. More particularly, the Regulations allow a generic manufacturer to recover the profits that it lost as a result of its generic version of a patented drug being kept off the market during the pendency of an unsuccessful court proceeding commenced by the patentee under the NOC Regulations.  

A further level of regulation over patented drugs is provided by the Patented Medicine Prices Review Board, which regulates the prices at which patented drugs may be sold in Canada.

None of the above statutes or regulations provides a cause of action to other persons in the channels of trade for a drug such as consumers, pharmacists, distributors or insurers. 


The first issue before the appellate court was whether the combination of these statutes and regulations (referred to as the Patent Regulatory Regime) constitute a complete legislative code as to the rights and remedies of patent holders and generic drug makers. Pfizer argued that the Canadian Parliament, having provided a limited cause of action to generic manufacturers under the NOC Regulations, must be presumed to have chosen not to create a right of action for consumers arising directly out of a breach of the Patent Act.  

Mr. Low, in response, argued that his claim was based entirely on common law and so the "complete code" argument did not apply. He further argued that because the Patent Regulatory Regime is silent as to consumer rights and remedies for breach of the Patent Act, it cannot be a complete code. The relevant question is therefore not whether Parliament intended to create a consumer right of action but rather whether it intended to oust such a right.

The BCCA began its analysis by noting that the Patent Regulatory Regime did not confer a direct benefit, right or protection on a consumer. The situation before the court was therefore distinguishable from previous cases where legislation created a right but did not provide an enforcement mechanism. In such cases, the absence of an enforcement mechanism could be taken as implying a common law private cause of action by a consumer.

The BCCA next cited the principle that there is no common law tort of breach of statute. Accordingly, there could be no tort of breach of the legislation forming the Patent Regulatory Regime.

The problem with Mr. Low's argument that his claim rested on a footing outside of the Patent Regulatory Regime, namely in the common law of unlawful interference with economic relations and in unjust enrichment, was that his pleading asserted that Pfizer's wrongful conduct was its failure to make disclosure of its invention as required by the Patent Act. As such, Mr. Low's claim was clearly a claim for breach of statute and his entitlement was alleged to arise out of abuse of the patent system.

The BCCA then went on to conclude that the completeness of the Patent Regulatory Regime forecloses civil actions by consumers that are rooted in a breach of the Patent Act. The BCCA noted that prior decisions had held that the completeness of the Patent Regulatory Regime prevented generic drug manufacturers from claiming disgorgement of profits based on unjust enrichment. It would be illogical to allow consumers to claim disgorgement of profits from brand manufacturers when generic manufacturers are themselves precluded from claiming the same recovery based on the identical allegedly wrongful acts.

The BCCA also noted that there was evidence that Parliament had considered the interests of consumers when creating the Patent Regulatory Regime. For example, the Patented Medicine Prices Review Board was given the power to reduce the prices of medicines where it deemed such prices to be excessive. Therefore, an inference could not be drawn that Parliament, in enacting the Patent Regulatory Regime, did not intend to oust consumer remedies.


The court's ruling that the Patent Regulatory Regime constituted a complete code defeated Mr. Low's claim. The BCCA went on, however, to hold that even if it had not ruled that the Patent Regulatory Regime constituted a complete code, it would nevertheless have not allowed certification of the claim in unlawful interference with economic relations.

The tort of unlawful interference with economic relations has three elements, namely: 

1. An unlawful act committed against a third party

2. Intended to cause economic harm to the plaintiff

3. Resulting in economic harm to the plaintiff. 

As such, this tort is sometimes described as creating a kind of "parasitic" liability since the plaintiff's claim is based on (or parasitic upon) the defendant's unlawful act against the third party.  

Mr. Low had argued that Pfizer, through its breach of the Patent Act, had committed an unlawful act against generic manufacturers which was intended to and, in fact, caused economic harm to VIAGRA purchasers. "Unlawful" conduct is conduct that would be actionable by the third party or would have been actionable if the third party had suffered loss as a result of it. 

The BCCA, noting that a generic manufacturer has no actionable claim against a patentee for unjust enrichment or disgorgement of profits, held that the tort of unlawful interference, which is based on a parasitic claim, could not possibly succeed.


The BCCA next considered the tort of unjust enrichment in the event that its ruling that the Patent Regulatory Regime constituted a complete code was, on further appeal, held to be incorrect.

The tort of unjust enrichment has three elements: 

1. An enrichment of the defendant

2. A corresponding deprivation of the plaintiff

3. An absence of juristic reasons for the enrichment.

Pfizer argued that its contracts with direct purchasers such as distributors and pharmacies constituted a juristic reason for the alleged enrichment. More particularly, the alleged overcharge (i.e., the price increase attributable to the existence and enforcement of the patent for VIAGRA) was passed on to the ultimate consumers through these contracts between Pfizer and the direct purchasers. Therefore, unless these contracts could be shown to be illegal or based on a common mistake, there was no basis to conclude the absence of a juristic reason.

In reviewing the chambers judge's reasons, the BCCA concluded that the judge had held that Pfizer's contracts with its direct purchasers constituted a juristic reason. Accordingly, the chambers judge should have found that this cause of action had no prospect of success.

The BCCA therefore held that the appeal should be allowed.


The BCCA's decision in Low v. Pfizer is certain to be influential in other cases involving allegations of patent abuse, whether in class action proceedings or otherwise.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
26 Oct 2018, Other, Vancouver, Canada

Cybersecurity, including data privacy and security obligations, has become a critical chapter in every company’s risk management playbook.

30 Oct 2018, Other, Toronto, Canada

Please join us for discussions on recent updates and legal developments in pension and employee benefits as well as employment law issues.

12 Nov 2018, Other, Toronto, Canada

Stories aren’t falsehoods. Stories are the root of all effective human communications: they motivate, animate and clarify. If you aren’t telling stories, you probably aren’t getting your point across.

Similar Articles
Relevancy Powered by MondaqAI
Norton Rose Fulbright Canada LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Norton Rose Fulbright Canada LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions